Resources

for Your Patients

Today’s Migraineur

Women and Migraines—Female Migraineurs Need Your Help

Today, many women live double days as they try to meet the growing demands of family, work, and friends. That’s why women affected by migraines will appreciate treatment options that provide migraine relief and a treatment program that can keep pace with their busy lifestyles.

Who Are Today’s Migraineurs?

28 million Americans experience migraines¹³
Over 21 million of them are women¹³
These 21 million female migraineurs are like most other women, leading demanding lives¹⁴
Typically working a "double day"¹⁵
A majority of women are responsible for home and work¹⁵

That's why they can't afford to lose time to migraines—and why the speed, power, and versatility of ZOMIG can help^1-9

Indication and Important Safety Considerations

ZOMIG is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established.

ZOMIG is not intended for the prophylactic therapy of migraine and is not indicated for the treatment of cluster headache.

ZOMIG is contraindicated in patients with
- Ischemic heart disease (eg, silent ischemia, angina), coronary artery vasospasm, or other significant underlying cardiovascular disease
- Cerebrovascular syndromes (eg, history of stroke or TIA)
- Peripheral vascular disease (eg, ischemic bowel disease)
- Uncontrolled hypertension
Use of ZOMIG is contraindicated within 24 hours of another 5-HT₁ agonist, ergotamine-containing or ergot-type medication, or within 2 weeks of an MAO-A inhibitor
ZOMIG should not be administered to patients with hemiplegic or basilar migraine
It is strongly recommended that ZOMIG not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors without a satisfactory cardiac evaluation
Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory cardiac conduction pathways should not receive ZOMIG
Development of potentially life-threatening serotonin syndrome may occur with triptans particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
Phenylketonuric patients should be informed that ZOMIG-ZMT^® (zolmitriptan) contains phenylalanine
ZOMIG should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus
Most common adverse reactions in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
Most common adverse reactions in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness

ZOMIG and ZOMIG-ZMT are registered trademarks of the AstraZeneca group of companies. This product information is intended for US health care professionals only.